We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hemogenyx Pharmaceuticals Plc | LSE:HEMO | London | Ordinary Share | GB00BYX3WZ24 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.015 | -0.96% | 1.55 | 1.536 | 1.598 | 1.55 | 1.55 | 1.55 | 4,707,352 | 15:17:40 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.98M | -0.0035 | -4.43 | 17.7M |
Date | Subject | Author | Discuss |
---|---|---|---|
05/3/2024 17:15 | Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "We are extremely pleased to have raised these funds to allow us to progress our lead asset, HEMO-CAR-T, to clinical trials. This is a key development that represents the progression of Hemogenyx Pharmaceuticals to become a clinical stage company and the fundraise was crucial to enable us to progress toward clinical trials, the essential next step for the development of HEMO-CAR-T." | apotheki | |
05/3/2024 17:05 | The funds have been raised to allow the Company to progress HEMO-CAR-T to phase 1 clinical trials. | apotheki | |
05/3/2024 17:05 | The Placing will be used to facilitate the development of the Company's Chimeric Antigen Receptor T-cells ("HEMO-CAR-T") for the treatment of acute myeloid leukaemia ("AML") | apotheki | |
05/3/2024 15:31 | What's the next step for HEMO | lemonadestand1 | |
05/3/2024 14:25 | Hey J J the most likely reason for volumes starting to drop off is in my opinion that the shares that required forward selling [ahead of tomorrow] have now already for the most part [95%+] been sold | apotheki | |
05/3/2024 14:20 | An application is being made to the London Stock Exchange Main Market and admission of the Placing Shares to trading is expected on or around 6 March 2024 | apotheki | |
05/3/2024 13:07 | Volumes dropping off now | jibba jabber | |
05/3/2024 09:31 | Vladislav Sandler is a deceiver, he has been deceiving shareholder for many many years, first he destroyed shareholder value by signing CLN agreement than every time he falsify and build hype to pump the price so he can raise more funds just to pay his own and his incompetent teams salaries. | trader4ever | |
04/3/2024 10:05 | And that is far too low given where the company are currently and more importantly where the company are potentially headed. Additionally the company are extremely undervalued when compared to their peer group especially in the USA | apotheki | |
04/3/2024 09:39 | 2p gives a MC valuation of over £26 million. | countbasie1 | |
02/3/2024 10:20 | So with all the forward selling from the placement that has already occurred [plus of course Monday & Tuesday] the coast should be for the most part a lot clearer from next Wednesday [6th March] for the shares to move back on up from the sub 2p levels! | apotheki | |
02/3/2024 10:15 | Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "We are extremely pleased to have raised these funds to allow us to progress our lead asset, HEMO-CAR-T, to clinical trials. This is a key development that represents the progression of Hemogenyx Pharmaceuticals to become a clinical stage company and the fundraise was crucial to enable us to progress toward clinical trials, the essential next step for the development of HEMO-CAR-T. I would like to thank new and existing shareholders for their support and for contributing to this sizeable fundraise in difficult market conditions. The recent lifting of the clinical hold by the FDA on our HEMO-CAR-T programme followed a great effort from everyone at Hemogenyx Pharmaceuticals for which I am very grateful." | apotheki | |
02/3/2024 10:10 | Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it raised US$4.2 million.... An application is being made to the London Stock Exchange Main Market and admission of the Placing Shares to trading is expected on or around 6 March 2024 | apotheki | |
01/3/2024 15:20 | Marcucci added, "This novel mechanism and the targeting by City of Hope's homegrown approach will allow us to eliminate otherwise dormant leukemi Try reading the articles you post Dreamy chops | saint in exile | |
01/3/2024 14:20 | Now that the main TROLLs have left this main HEMO thread why don't you decent posters engage over here instead of on the dark side? | apotheki | |
01/3/2024 14:17 | saint in exile 1 Mar '24 - 11:57 - 8809 of 8811 I suggest you research some of the buy outs for T CAR companies in recent times.The sector is very much in its infancy | apotheki | |
01/3/2024 12:02 | Be my guest & buy above the market value ⚓ | dreamtwister | |
01/3/2024 11:58 | If it wasnt cancer wouldn't exist | saint in exile | |
01/3/2024 11:57 | I suggest you research some of the buy outs for T CAR companies in recent times.The sector is very much in its infancy | saint in exile | |
01/3/2024 11:35 | saint in exile 1 Mar '24 - 11:19 - 8806 of 8806 So what.You need funding to unlock this tech.who knew.Some of us are more interested in the end game and yes that involves placings and risk.You either take the chance or you dont.Its not like some kind of con trick.Vlad is really trying to save lives.Maybe even your mums Dreamyif you have one | apotheki | |
01/3/2024 11:19 | So what.You need funding to unlock this tech.who knew.Some of us are more interested in the end game and yes that involves placings and risk.You either take the chance or you dont.Its not like some kind of con trick.Vlad is really trying to save lives.Maybe even your mums Dreamyif you have one | saint in exile |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions